These findings may explain one of the reasons for the suboptimal efficacy of simvastatin in the treatment of pancreatic cancer, while also providing new insights for research on the antitumor effects of statins.

PPC combined with ATV is superior to PPC alone in improving the liver function, lipid metabolism, inflammation and liver injury without increasing the adverse reactions. It may represent a safe adjunct strategy in MAFLD management.

Atorvastatin combined with argatroban can effectively improve the cerebral hemodynamics, coagulation and endothelial function and reduce the inflammation in ACI patients, thus exerting a good therapeutic efficacy.

P2, N=256, Recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: Nov 2028 --> Aug 2029 | Trial primary completion date: Nov 2028 --> Aug 2029

Importantly, two clinical drugs, the RhoA inhibitor simvastatin and the YAP1/TEAD inhibitor verteporfin were determined to be the disruptors of this feed-forward signaling axis, inhibiting ICC tumor growth. These findings reveal the vital function of ANLN in ICC growth and provide promising treatment strategies for ICC.

To investigate this, we synthesized statin-dye conjugates by attaching a fluorescent dye (Cy5.5) to two statins: simvastatin and pravastatin, aiming to assess whether selective uptake indeed occurs. Notably, in the PCC and CAF co-culture model, the pravastatin-Cy5.5 conjugate selectively killed KRASMUT PCCs without affecting the KRASWT CAFs. These findings highlight the unique synergistic potential of statin-Cy5.5-distinct from either component alone-as targeted delivery vehicles for KRASMUT cancer therapy.

Of translational impact, we observed that neratinib, in conjunction with the use of rosuvastatin (a standard lipid-lowering drug), produced superior antiatherosclerotic effects compared with statin monotherapy. Olink proteomics study pinpointed that combination treatment alleviated inflammation-related cytokines/chemokines in the serum from Ldlr-/- mice. Taken together, these findings support the concept that neratinib could be tested as a repurposed drug for vascular inflammation and atherosclerosis, thereby streamlining efforts to translate preclinical discoveries to clinical testing in humans.

We developed an orally administrable nanoplatform (MCT-NE#9) co-delivering docetaxel (DTX) and atorvastatin (ATV), designed to enhance intestinal uptake via bile acid and vitamin transporters. MCT-NE#9 enables a synergistic, low-toxicity chemo-immunotherapeutic strategy by sustaining ferroptosis and reprogramming the immune microenvironment via transporter-targeted oral delivery. This ligand-directed nanoplatform offers a clinically translatable approach for effective TNBC treatment.

C57BL/6J mice were randomized into control, model, pravastatin(40 mg·kg~(-1)), and low-(1.3 g·kg~(-1)), medium-(2.6 g·kg~(-1)), and high-dose(5.2 g·kg~(-1)) QD-WXF groups. In the experiment with STING~(KO), there was no significant difference between the QD-WXF group and the model group, while significant differences existed between the WT model group and the STING~(KO) model group. The above results indicate that QD-WXF can effectively alleviate doxorubicin-induced cardiotoxicity by inhibiting the inflammation via the cGAS/STING/NF-κB pathway.

P3, N=142, Active, not recruiting, VA Office of Research and Development | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=24, Recruiting, Beijing Inno Medicine Co., Ltd. | N=12 --> 24 | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Jun 2026

P1, N=15, Recruiting, Children's Mercy Hospital Kansas City | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026